| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 199 | 2023 | 559 | 41.010 |
Why?
|
| Arthroplasty, Replacement, Hip | 201 | 2023 | 699 | 40.320 |
Why?
|
| Prosthesis-Related Infections | 89 | 2023 | 177 | 20.230 |
Why?
|
| Hip Prosthesis | 87 | 2023 | 443 | 16.390 |
Why?
|
| Reoperation | 122 | 2023 | 767 | 11.590 |
Why?
|
| Knee Prosthesis | 56 | 2023 | 203 | 11.150 |
Why?
|
| Prosthesis Failure | 63 | 2023 | 424 | 7.690 |
Why?
|
| Humans | 367 | 2023 | 23569 | 7.570 |
Why?
|
| Osteoarthritis, Knee | 28 | 2023 | 299 | 6.790 |
Why?
|
| Postoperative Complications | 55 | 2023 | 837 | 6.640 |
Why?
|
| Arthritis, Infectious | 24 | 2023 | 48 | 6.440 |
Why?
|
| Knee Joint | 54 | 2023 | 577 | 6.140 |
Why?
|
| Retrospective Studies | 113 | 2023 | 3122 | 5.740 |
Why?
|
| Aged | 170 | 2022 | 7586 | 5.620 |
Why?
|
| Pain, Postoperative | 29 | 2022 | 283 | 5.600 |
Why?
|
| Middle Aged | 177 | 2022 | 8155 | 5.310 |
Why?
|
| Female | 198 | 2022 | 13266 | 4.940 |
Why?
|
| Analgesics, Opioid | 19 | 2022 | 215 | 4.730 |
Why?
|
| Male | 186 | 2022 | 12776 | 4.710 |
Why?
|
| Prosthesis Design | 56 | 2023 | 394 | 4.680 |
Why?
|
| Hip Dislocation | 13 | 2023 | 59 | 4.440 |
Why?
|
| Orthopedic Surgeons | 9 | 2022 | 24 | 4.430 |
Why?
|
| Tranexamic Acid | 10 | 2021 | 17 | 4.310 |
Why?
|
| Surgical Wound Infection | 13 | 2019 | 80 | 4.260 |
Why?
|
| Synovial Fluid | 25 | 2020 | 82 | 4.220 |
Why?
|
| Aged, 80 and over | 96 | 2022 | 3770 | 4.090 |
Why?
|
| Treatment Outcome | 96 | 2023 | 3095 | 4.030 |
Why?
|
| Hip Joint | 23 | 2020 | 388 | 3.820 |
Why?
|
| Periprosthetic Fractures | 10 | 2023 | 26 | 3.700 |
Why?
|
| Antifibrinolytic Agents | 9 | 2020 | 16 | 3.610 |
Why?
|
| Adult | 115 | 2022 | 7178 | 3.600 |
Why?
|
| Nerve Block | 5 | 2022 | 62 | 3.420 |
Why?
|
| Risk Factors | 55 | 2023 | 1997 | 3.420 |
Why?
|
| United States | 51 | 2022 | 1837 | 3.390 |
Why?
|
| Anesthesia, Conduction | 7 | 2022 | 31 | 3.380 |
Why?
|
| Outpatients | 11 | 2023 | 56 | 3.330 |
Why?
|
| Hip Fractures | 10 | 2023 | 23 | 3.300 |
Why?
|
| Anti-Bacterial Agents | 24 | 2021 | 366 | 3.290 |
Why?
|
| Femoral Fractures | 12 | 2021 | 32 | 3.200 |
Why?
|
| Arthroplasty, Replacement | 11 | 2020 | 129 | 3.050 |
Why?
|
| Acetabulum | 18 | 2021 | 192 | 2.990 |
Why?
|
| Pneumonia | 7 | 2019 | 69 | 2.780 |
Why?
|
| Inpatients | 10 | 2022 | 116 | 2.750 |
Why?
|
| Surgeons | 10 | 2022 | 79 | 2.710 |
Why?
|
| Patient Readmission | 17 | 2022 | 118 | 2.620 |
Why?
|
| Orthopedics | 8 | 2019 | 83 | 2.590 |
Why?
|
| Urinary Tract Infections | 5 | 2022 | 31 | 2.520 |
Why?
|
| Venous Thrombosis | 7 | 2023 | 40 | 2.480 |
Why?
|
| Medicare | 17 | 2022 | 107 | 2.400 |
Why?
|
| Osteoarthritis, Hip | 13 | 2020 | 88 | 2.260 |
Why?
|
| Sepsis | 8 | 2018 | 112 | 2.230 |
Why?
|
| C-Reactive Protein | 19 | 2019 | 92 | 2.230 |
Why?
|
| Joint Dislocations | 7 | 2023 | 50 | 2.140 |
Why?
|
| Length of Stay | 17 | 2023 | 305 | 2.090 |
Why?
|
| Joint Instability | 13 | 2018 | 325 | 2.060 |
Why?
|
| Radiography | 38 | 2020 | 556 | 2.060 |
Why?
|
| Pulmonary Embolism | 6 | 2022 | 56 | 1.980 |
Why?
|
| Blood Loss, Surgical | 9 | 2020 | 53 | 1.920 |
Why?
|
| Malnutrition | 4 | 2015 | 22 | 1.820 |
Why?
|
| Pain Management | 12 | 2022 | 132 | 1.800 |
Why?
|
| Operative Time | 8 | 2021 | 82 | 1.790 |
Why?
|
| Range of Motion, Articular | 21 | 2023 | 602 | 1.730 |
Why?
|
| Femur | 18 | 2020 | 310 | 1.710 |
Why?
|
| Patient Discharge | 10 | 2023 | 146 | 1.700 |
Why?
|
| Osteotomy | 10 | 2020 | 128 | 1.670 |
Why?
|
| Patient Satisfaction | 11 | 2019 | 271 | 1.660 |
Why?
|
| Metals | 14 | 2019 | 99 | 1.640 |
Why?
|
| Analgesia | 5 | 2022 | 35 | 1.630 |
Why?
|
| Joint Diseases | 7 | 2017 | 95 | 1.620 |
Why?
|
| Pain | 15 | 2022 | 348 | 1.580 |
Why?
|
| Arthroplasty | 10 | 2022 | 117 | 1.570 |
Why?
|
| Follow-Up Studies | 35 | 2021 | 1493 | 1.540 |
Why?
|
| Anesthetics | 2 | 2022 | 19 | 1.540 |
Why?
|
| Polyethylene | 10 | 2021 | 95 | 1.530 |
Why?
|
| Blood Sedimentation | 17 | 2019 | 49 | 1.510 |
Why?
|
| Young Adult | 24 | 2021 | 1747 | 1.500 |
Why?
|
| Time Factors | 32 | 2020 | 1295 | 1.460 |
Why?
|
| Prospective Studies | 32 | 2021 | 1535 | 1.460 |
Why?
|
| Tibia | 11 | 2021 | 198 | 1.450 |
Why?
|
| Metal-on-Metal Joint Prostheses | 7 | 2021 | 33 | 1.450 |
Why?
|
| Biomarkers | 14 | 2018 | 482 | 1.440 |
Why?
|
| Bone Cements | 13 | 2023 | 79 | 1.430 |
Why?
|
| Risk Assessment | 16 | 2021 | 556 | 1.290 |
Why?
|
| Adolescent | 21 | 2021 | 1953 | 1.210 |
Why?
|
| Femur Head | 5 | 2023 | 51 | 1.210 |
Why?
|
| Debridement | 11 | 2020 | 74 | 1.200 |
Why?
|
| Quality Improvement | 12 | 2018 | 128 | 1.200 |
Why?
|
| Ambulatory Surgical Procedures | 7 | 2021 | 65 | 1.180 |
Why?
|
| Hospital Costs | 3 | 2017 | 58 | 1.160 |
Why?
|
| Postoperative Hemorrhage | 3 | 2019 | 22 | 1.160 |
Why?
|
| Physical Therapy Modalities | 3 | 2019 | 61 | 1.150 |
Why?
|
| Multivariate Analysis | 9 | 2019 | 299 | 1.150 |
Why?
|
| Recovery of Function | 19 | 2017 | 255 | 1.150 |
Why?
|
| alpha-Defensins | 2 | 2018 | 3 | 1.150 |
Why?
|
| Health Care Costs | 4 | 2022 | 62 | 1.120 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 125 | 1.120 |
Why?
|
| Intraoperative Care | 5 | 2021 | 41 | 1.100 |
Why?
|
| Analgesia, Epidural | 2 | 2018 | 54 | 1.100 |
Why?
|
| Therapeutic Irrigation | 10 | 2020 | 48 | 1.090 |
Why?
|
| Comorbidity | 12 | 2022 | 431 | 1.080 |
Why?
|
| Serum Albumin | 3 | 2021 | 21 | 1.080 |
Why?
|
| Adrenal Cortex Hormones | 6 | 2022 | 100 | 1.070 |
Why?
|
| Intraoperative Complications | 4 | 2016 | 61 | 1.060 |
Why?
|
| Orthopedic Procedures | 7 | 2019 | 240 | 1.060 |
Why?
|
| Coated Materials, Biocompatible | 7 | 2015 | 38 | 1.060 |
Why?
|
| Thromboembolism | 4 | 2018 | 17 | 1.060 |
Why?
|
| Anesthesia | 2 | 2022 | 28 | 1.060 |
Why?
|
| Ownership | 2 | 2017 | 6 | 1.050 |
Why?
|
| Anesthetics, Local | 3 | 2022 | 71 | 1.050 |
Why?
|
| Leukocyte Count | 13 | 2020 | 58 | 1.030 |
Why?
|
| Blood Transfusion | 6 | 2022 | 59 | 1.000 |
Why?
|
| Foreign-Body Reaction | 2 | 2016 | 16 | 0.990 |
Why?
|
| Ambulatory Care | 2 | 2021 | 66 | 0.990 |
Why?
|
| Registries | 8 | 2018 | 179 | 0.970 |
Why?
|
| Societies, Medical | 5 | 2021 | 119 | 0.970 |
Why?
|
| Incidence | 15 | 2018 | 644 | 0.970 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 244 | 0.960 |
Why?
|
| Chromium | 6 | 2018 | 62 | 0.960 |
Why?
|
| Ketamine | 2 | 2022 | 23 | 0.960 |
Why?
|
| Sensitivity and Specificity | 16 | 2019 | 453 | 0.950 |
Why?
|
| Postoperative Period | 11 | 2020 | 269 | 0.950 |
Why?
|
| Hemiarthroplasty | 2 | 2017 | 31 | 0.950 |
Why?
|
| Cobalt | 6 | 2018 | 76 | 0.950 |
Why?
|
| Surveys and Questionnaires | 18 | 2020 | 1046 | 0.940 |
Why?
|
| Tendinopathy | 2 | 2022 | 41 | 0.940 |
Why?
|
| Body Mass Index | 11 | 2020 | 403 | 0.930 |
Why?
|
| Prostheses and Implants | 5 | 2017 | 129 | 0.920 |
Why?
|
| Cohort Studies | 14 | 2021 | 1466 | 0.900 |
Why?
|
| Morphine | 3 | 2022 | 70 | 0.890 |
Why?
|
| Algorithms | 11 | 2022 | 317 | 0.870 |
Why?
|
| Braces | 2 | 2016 | 20 | 0.870 |
Why?
|
| Vancomycin | 4 | 2019 | 52 | 0.870 |
Why?
|
| Odds Ratio | 8 | 2019 | 230 | 0.860 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2019 | 50 | 0.850 |
Why?
|
| Osseointegration | 6 | 2016 | 64 | 0.850 |
Why?
|
| Arthritis | 3 | 2020 | 45 | 0.840 |
Why?
|
| Prescriptions | 2 | 2021 | 16 | 0.830 |
Why?
|
| Infection Control | 5 | 2013 | 169 | 0.820 |
Why?
|
| Hospitals | 4 | 2018 | 157 | 0.820 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2019 | 98 | 0.820 |
Why?
|
| Acetaminophen | 2 | 2020 | 22 | 0.820 |
Why?
|
| Sex Factors | 7 | 2019 | 393 | 0.810 |
Why?
|
| Pain Measurement | 12 | 2022 | 429 | 0.810 |
Why?
|
| Hypoalbuminemia | 3 | 2021 | 4 | 0.790 |
Why?
|
| Urinary Retention | 1 | 2022 | 12 | 0.790 |
Why?
|
| Bursitis | 1 | 2022 | 11 | 0.780 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 91 | 0.780 |
Why?
|
| Patellofemoral Joint | 3 | 2023 | 47 | 0.780 |
Why?
|
| Allografts | 3 | 2023 | 149 | 0.780 |
Why?
|
| Patient Selection | 8 | 2014 | 170 | 0.770 |
Why?
|
| Osteoporosis | 1 | 2023 | 71 | 0.770 |
Why?
|
| Joint Prosthesis | 2 | 2015 | 75 | 0.750 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2013 | 47 | 0.740 |
Why?
|
| Opioid-Related Disorders | 2 | 2020 | 57 | 0.740 |
Why?
|
| Home Care Services | 1 | 2021 | 21 | 0.730 |
Why?
|
| Osteolysis | 5 | 2015 | 113 | 0.730 |
Why?
|
| Fracture Fixation, Internal | 5 | 2013 | 57 | 0.710 |
Why?
|
| Hospitalization | 2 | 2021 | 293 | 0.710 |
Why?
|
| Analgesics | 6 | 2022 | 78 | 0.700 |
Why?
|
| Databases, Factual | 10 | 2022 | 316 | 0.690 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2019 | 168 | 0.680 |
Why?
|
| Osteoarthritis | 3 | 2022 | 289 | 0.680 |
Why?
|
| Nail-Patella Syndrome | 1 | 2020 | 2 | 0.670 |
Why?
|
| Corrosion | 7 | 2018 | 92 | 0.670 |
Why?
|
| Refuse Disposal | 1 | 2020 | 2 | 0.670 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 7 | 0.660 |
Why?
|
| Hemoglobins | 3 | 2019 | 27 | 0.650 |
Why?
|
| Preoperative Care | 9 | 2012 | 112 | 0.650 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 66 | 0.640 |
Why?
|
| Anticoagulants | 6 | 2016 | 84 | 0.640 |
Why?
|
| Bone Transplantation | 2 | 2020 | 156 | 0.630 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2017 | 43 | 0.630 |
Why?
|
| Quality of Life | 5 | 2020 | 565 | 0.620 |
Why?
|
| Injections, Intra-Articular | 4 | 2022 | 58 | 0.620 |
Why?
|
| Surgical Wound | 2 | 2018 | 9 | 0.610 |
Why?
|
| Oxycodone | 1 | 2019 | 4 | 0.610 |
Why?
|
| Medial Collateral Ligament, Knee | 2 | 2016 | 5 | 0.610 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 19 | 0.600 |
Why?
|
| Frozen Sections | 4 | 2018 | 14 | 0.600 |
Why?
|
| Patient Preference | 1 | 2019 | 33 | 0.600 |
Why?
|
| ROC Curve | 8 | 2019 | 127 | 0.590 |
Why?
|
| Fracture Fixation, Intramedullary | 2 | 2017 | 7 | 0.590 |
Why?
|
| Carboxylic Ester Hydrolases | 4 | 2019 | 4 | 0.580 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2018 | 4 | 0.580 |
Why?
|
| Patient Care Bundles | 1 | 2018 | 2 | 0.570 |
Why?
|
| Risk Adjustment | 1 | 2018 | 9 | 0.570 |
Why?
|
| Elective Surgical Procedures | 6 | 2019 | 32 | 0.570 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 72 | 0.570 |
Why?
|
| Rehabilitation | 1 | 2018 | 11 | 0.570 |
Why?
|
| Predictive Value of Tests | 13 | 2017 | 443 | 0.560 |
Why?
|
| Hospitals, Private | 1 | 2017 | 3 | 0.560 |
Why?
|
| Internship and Residency | 3 | 2019 | 204 | 0.560 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 19 | 0.550 |
Why?
|
| Acute Disease | 6 | 2017 | 169 | 0.550 |
Why?
|
| Patient Safety | 1 | 2018 | 35 | 0.550 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 5 | 0.550 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 7 | 0.550 |
Why?
|
| Antibiotic Prophylaxis | 4 | 2014 | 27 | 0.550 |
Why?
|
| Device Removal | 8 | 2014 | 68 | 0.550 |
Why?
|
| Porosity | 9 | 2022 | 55 | 0.540 |
Why?
|
| Equipment Failure Analysis | 6 | 2015 | 81 | 0.540 |
Why?
|
| Recurrence | 9 | 2018 | 276 | 0.540 |
Why?
|
| Calcium Sulfate | 1 | 2017 | 8 | 0.530 |
Why?
|
| Bone Plates | 3 | 2017 | 41 | 0.530 |
Why?
|
| Exercise Therapy | 1 | 2018 | 85 | 0.530 |
Why?
|
| Chicago | 7 | 2018 | 818 | 0.530 |
Why?
|
| Hospital Mortality | 1 | 2017 | 133 | 0.530 |
Why?
|
| Regression Analysis | 5 | 2023 | 220 | 0.530 |
Why?
|
| Ceramics | 2 | 2015 | 12 | 0.520 |
Why?
|
| Povidone-Iodine | 2 | 2019 | 5 | 0.520 |
Why?
|
| Diabetes Complications | 1 | 2017 | 44 | 0.520 |
Why?
|
| Practice Management | 1 | 2016 | 2 | 0.510 |
Why?
|
| Emergency Service, Hospital | 4 | 2021 | 254 | 0.500 |
Why?
|
| Biomechanical Phenomena | 8 | 2018 | 556 | 0.490 |
Why?
|
| Physicians | 1 | 2017 | 108 | 0.490 |
Why?
|
| Commerce | 1 | 2016 | 10 | 0.490 |
Why?
|
| Logistic Models | 5 | 2019 | 357 | 0.490 |
Why?
|
| Attitude to Health | 2 | 2016 | 94 | 0.490 |
Why?
|
| Ketorolac | 3 | 2022 | 12 | 0.490 |
Why?
|
| Bone Screws | 4 | 2017 | 130 | 0.480 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2019 | 368 | 0.480 |
Why?
|
| Conflict of Interest | 1 | 2015 | 9 | 0.470 |
Why?
|
| Sutures | 2 | 2012 | 39 | 0.450 |
Why?
|
| Knee | 4 | 2020 | 38 | 0.450 |
Why?
|
| Nutritional Status | 1 | 2015 | 53 | 0.450 |
Why?
|
| Microbiological Techniques | 2 | 2013 | 6 | 0.440 |
Why?
|
| Drainage | 2 | 2018 | 41 | 0.440 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 60 | 0.430 |
Why?
|
| Reagent Strips | 2 | 2016 | 3 | 0.420 |
Why?
|
| Disinfection | 1 | 2013 | 11 | 0.410 |
Why?
|
| Postoperative Care | 4 | 2016 | 114 | 0.410 |
Why?
|
| Internal Fixators | 2 | 2010 | 34 | 0.400 |
Why?
|
| Health Expenditures | 3 | 2018 | 15 | 0.400 |
Why?
|
| Patellar Ligament | 2 | 2015 | 35 | 0.400 |
Why?
|
| Chlorhexidine | 1 | 2013 | 62 | 0.400 |
Why?
|
| Disclosure | 3 | 2019 | 12 | 0.390 |
Why?
|
| Femoral Nerve | 3 | 2022 | 9 | 0.380 |
Why?
|
| Reproducibility of Results | 7 | 2019 | 603 | 0.380 |
Why?
|
| Walking | 4 | 2018 | 237 | 0.380 |
Why?
|
| Diphosphonates | 2 | 2023 | 15 | 0.370 |
Why?
|
| Awards and Prizes | 5 | 2017 | 21 | 0.370 |
Why?
|
| Arthroscopy | 3 | 2016 | 742 | 0.360 |
Why?
|
| Enterococcus | 3 | 2017 | 55 | 0.350 |
Why?
|
| Serologic Tests | 1 | 2011 | 8 | 0.350 |
Why?
|
| Blood Coagulation | 1 | 2011 | 20 | 0.350 |
Why?
|
| Suture Techniques | 1 | 2011 | 123 | 0.340 |
Why?
|
| Genetic Testing | 1 | 2011 | 46 | 0.340 |
Why?
|
| Fractures, Ununited | 1 | 2010 | 15 | 0.330 |
Why?
|
| Cost-Benefit Analysis | 3 | 2022 | 112 | 0.330 |
Why?
|
| Tantalum | 4 | 2017 | 22 | 0.330 |
Why?
|
| Prevalence | 6 | 2013 | 395 | 0.330 |
Why?
|
| Perioperative Care | 1 | 2010 | 42 | 0.330 |
Why?
|
| Administration, Oral | 4 | 2020 | 99 | 0.320 |
Why?
|
| Risk | 3 | 2019 | 164 | 0.320 |
Why?
|
| Intra-Articular Fractures | 1 | 2010 | 12 | 0.320 |
Why?
|
| Quality of Health Care | 4 | 2018 | 96 | 0.320 |
Why?
|
| Pelvic Bones | 1 | 2010 | 17 | 0.320 |
Why?
|
| Minimally Invasive Surgical Procedures | 6 | 2017 | 294 | 0.320 |
Why?
|
| Dexamethasone | 2 | 2022 | 34 | 0.320 |
Why?
|
| Bupivacaine | 2 | 2022 | 40 | 0.310 |
Why?
|
| Bone Nails | 2 | 2007 | 13 | 0.310 |
Why?
|
| Titanium | 5 | 2016 | 141 | 0.310 |
Why?
|
| Age Factors | 7 | 2018 | 648 | 0.310 |
Why?
|
| Leg Length Inequality | 2 | 2016 | 9 | 0.300 |
Why?
|
| Double-Blind Method | 4 | 2022 | 383 | 0.300 |
Why?
|
| Venous Thromboembolism | 3 | 2016 | 32 | 0.300 |
Why?
|
| Device Approval | 1 | 2008 | 2 | 0.300 |
Why?
|
| Chromium Alloys | 4 | 2021 | 30 | 0.300 |
Why?
|
| Chi-Square Distribution | 5 | 2016 | 126 | 0.300 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 18 | 0.300 |
Why?
|
| Neutrophils | 5 | 2020 | 93 | 0.300 |
Why?
|
| Achilles Tendon | 1 | 2008 | 12 | 0.290 |
Why?
|
| Reimbursement Mechanisms | 2 | 2012 | 8 | 0.290 |
Why?
|
| Cementation | 6 | 2010 | 30 | 0.290 |
Why?
|
| Transplantation, Homologous | 4 | 2023 | 200 | 0.290 |
Why?
|
| Network Meta-Analysis | 2 | 2018 | 24 | 0.290 |
Why?
|
| Arthralgia | 2 | 2022 | 108 | 0.290 |
Why?
|
| Area Under Curve | 4 | 2018 | 59 | 0.290 |
Why?
|
| Staphylococcus aureus | 2 | 2019 | 70 | 0.280 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2018 | 12 | 0.280 |
Why?
|
| Preoperative Period | 2 | 2020 | 68 | 0.280 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 819 | 0.270 |
Why?
|
| Ambulatory Care Facilities | 2 | 2018 | 34 | 0.260 |
Why?
|
| Administration, Intravenous | 2 | 2017 | 23 | 0.260 |
Why?
|
| Iliac Artery | 2 | 2009 | 5 | 0.250 |
Why?
|
| Bone Malalignment | 2 | 2021 | 16 | 0.250 |
Why?
|
| Femoral Neck Fractures | 3 | 2018 | 9 | 0.250 |
Why?
|
| Prognosis | 4 | 2017 | 749 | 0.250 |
Why?
|
| Warfarin | 3 | 2016 | 25 | 0.250 |
Why?
|
| Diagnostic Imaging | 2 | 2020 | 74 | 0.240 |
Why?
|
| Disease Management | 3 | 2015 | 100 | 0.240 |
Why?
|
| Joints | 2 | 2016 | 67 | 0.240 |
Why?
|
| Child, Preschool | 2 | 2020 | 583 | 0.240 |
Why?
|
| Physician-Patient Relations | 2 | 2016 | 38 | 0.240 |
Why?
|
| Spine | 2 | 2018 | 99 | 0.230 |
Why?
|
| Ultrasonography, Doppler, Duplex | 2 | 2011 | 14 | 0.230 |
Why?
|
| Skilled Nursing Facilities | 2 | 2022 | 27 | 0.230 |
Why?
|
| Cartilage, Articular | 3 | 2017 | 279 | 0.230 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2016 | 55 | 0.220 |
Why?
|
| Wound Healing | 3 | 2018 | 123 | 0.220 |
Why?
|
| Propensity Score | 3 | 2021 | 35 | 0.220 |
Why?
|
| Internet | 3 | 2022 | 82 | 0.220 |
Why?
|
| Clinical Competence | 3 | 2019 | 202 | 0.220 |
Why?
|
| Terminology as Topic | 2 | 2016 | 32 | 0.210 |
Why?
|
| Pregabalin | 3 | 2020 | 14 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 908 | 0.210 |
Why?
|
| Heparin | 2 | 2002 | 22 | 0.210 |
Why?
|
| Chronic Disease | 6 | 2020 | 391 | 0.210 |
Why?
|
| Child | 2 | 2020 | 1178 | 0.210 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2023 | 11 | 0.200 |
Why?
|
| Patella | 4 | 2015 | 55 | 0.200 |
Why?
|
| Urinary Catheters | 1 | 2022 | 3 | 0.200 |
Why?
|
| Fracture Fixation | 1 | 2003 | 20 | 0.200 |
Why?
|
| Consensus | 2 | 2021 | 85 | 0.200 |
Why?
|
| Urinary Catheterization | 1 | 2022 | 6 | 0.200 |
Why?
|
| Psoas Muscles | 1 | 2022 | 6 | 0.200 |
Why?
|
| Femur Head Necrosis | 3 | 2012 | 7 | 0.200 |
Why?
|
| Catheters | 1 | 2022 | 15 | 0.200 |
Why?
|
| Clonidine | 1 | 2022 | 17 | 0.200 |
Why?
|
| Nausea | 1 | 2022 | 24 | 0.200 |
Why?
|
| Vomiting | 1 | 2022 | 18 | 0.200 |
Why?
|
| Cholecalciferol | 1 | 2022 | 6 | 0.190 |
Why?
|
| Crowdsourcing | 1 | 2022 | 1 | 0.190 |
Why?
|
| Epinephrine | 1 | 2022 | 29 | 0.190 |
Why?
|
| Early Diagnosis | 2 | 2014 | 51 | 0.190 |
Why?
|
| Early Ambulation | 3 | 2019 | 14 | 0.190 |
Why?
|
| Specimen Handling | 2 | 2020 | 40 | 0.190 |
Why?
|
| Ultrasonography, Interventional | 1 | 2022 | 64 | 0.190 |
Why?
|
| Bandages | 1 | 2002 | 4 | 0.190 |
Why?
|
| Equipment Design | 3 | 2011 | 124 | 0.190 |
Why?
|
| Muscle, Skeletal | 3 | 2018 | 337 | 0.190 |
Why?
|
| Anesthesia, General | 1 | 2022 | 23 | 0.190 |
Why?
|
| Fractures, Bone | 1 | 2003 | 70 | 0.180 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2002 | 39 | 0.180 |
Why?
|
| Anterior Cruciate Ligament Reconstruction | 2 | 2021 | 139 | 0.180 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 105 | 0.180 |
Why?
|
| Learning Curve | 1 | 2021 | 16 | 0.180 |
Why?
|
| Fibrinolytic Agents | 1 | 2002 | 59 | 0.180 |
Why?
|
| Anterior Cruciate Ligament | 2 | 2021 | 139 | 0.180 |
Why?
|
| Iliac Vein | 1 | 2001 | 3 | 0.170 |
Why?
|
| Tobramycin | 2 | 2018 | 8 | 0.170 |
Why?
|
| Lumbosacral Plexus | 1 | 2001 | 5 | 0.170 |
Why?
|
| Gentamicins | 2 | 2018 | 18 | 0.170 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2011 | 25 | 0.170 |
Why?
|
| Contraindications | 3 | 2013 | 26 | 0.170 |
Why?
|
| Morbidity | 2 | 2017 | 51 | 0.170 |
Why?
|
| Cluster Analysis | 1 | 2020 | 41 | 0.170 |
Why?
|
| Synovial Membrane | 3 | 2013 | 47 | 0.160 |
Why?
|
| Single-Blind Method | 1 | 2020 | 90 | 0.160 |
Why?
|
| Benzodiazepines | 1 | 2020 | 45 | 0.160 |
Why?
|
| Bacitracin | 1 | 2019 | 1 | 0.160 |
Why?
|
| Polymyxins | 1 | 2019 | 1 | 0.160 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 88 | 0.160 |
Why?
|
| Escherichia coli | 1 | 2019 | 46 | 0.160 |
Why?
|
| Tendons | 3 | 2006 | 183 | 0.160 |
Why?
|
| Perioperative Period | 2 | 2017 | 8 | 0.160 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1050 | 0.160 |
Why?
|
| Gallium | 2 | 2016 | 3 | 0.150 |
Why?
|
| Attitude | 1 | 2019 | 31 | 0.150 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1999 | 1 | 0.150 |
Why?
|
| Embolism, Paradoxical | 1 | 1999 | 2 | 0.150 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 36 | 0.150 |
Why?
|
| Staphylococcal Infections | 3 | 2017 | 157 | 0.150 |
Why?
|
| Fracture Healing | 3 | 2010 | 32 | 0.150 |
Why?
|
| Illinois | 3 | 2018 | 222 | 0.150 |
Why?
|
| Life Expectancy | 1 | 2018 | 24 | 0.150 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2018 | 7 | 0.140 |
Why?
|
| Disability Evaluation | 3 | 2014 | 220 | 0.140 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 127 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2016 | 72 | 0.140 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 41 | 0.140 |
Why?
|
| Heart Arrest | 1 | 2019 | 39 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 32 | 0.140 |
Why?
|
| Hand | 1 | 2018 | 39 | 0.140 |
Why?
|
| Injury Severity Score | 1 | 2017 | 10 | 0.140 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 126 | 0.140 |
Why?
|
| Anemia | 1 | 2018 | 30 | 0.140 |
Why?
|
| False Positive Reactions | 1 | 2018 | 31 | 0.140 |
Why?
|
| Activities of Daily Living | 3 | 2020 | 430 | 0.140 |
Why?
|
| Thigh | 1 | 2017 | 28 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 254 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 172 | 0.140 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 37 | 0.140 |
Why?
|
| Counseling | 1 | 2017 | 39 | 0.140 |
Why?
|
| Hospital Charges | 1 | 2017 | 15 | 0.140 |
Why?
|
| Health Policy | 1 | 2017 | 34 | 0.140 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2019 | 251 | 0.140 |
Why?
|
| Reading | 1 | 2017 | 23 | 0.140 |
Why?
|
| Leukocytes | 1 | 2017 | 31 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 276 | 0.130 |
Why?
|
| Comprehension | 1 | 2017 | 26 | 0.130 |
Why?
|
| Health Status | 1 | 2018 | 203 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 324 | 0.130 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 159 | 0.130 |
Why?
|
| Survival Rate | 1 | 2017 | 323 | 0.130 |
Why?
|
| Decision Trees | 2 | 2011 | 14 | 0.130 |
Why?
|
| Knee Injuries | 2 | 2015 | 127 | 0.130 |
Why?
|
| Vasculitis | 1 | 2016 | 26 | 0.130 |
Why?
|
| Cartilage Diseases | 1 | 2017 | 47 | 0.130 |
Why?
|
| Prosthesis Fitting | 3 | 2012 | 17 | 0.130 |
Why?
|
| Arthrocentesis | 1 | 2016 | 2 | 0.130 |
Why?
|
| Pelvis | 1 | 2016 | 25 | 0.130 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 24 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 606 | 0.120 |
Why?
|
| Ethics, Medical | 1 | 2016 | 6 | 0.120 |
Why?
|
| Cost Savings | 1 | 2016 | 29 | 0.120 |
Why?
|
| Nanostructures | 1 | 2016 | 9 | 0.120 |
Why?
|
| Replantation | 1 | 2016 | 9 | 0.120 |
Why?
|
| Silver | 1 | 2015 | 3 | 0.120 |
Why?
|
| Aspirin | 2 | 2010 | 50 | 0.120 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 32 | 0.120 |
Why?
|
| Acinetobacter baumannii | 1 | 2015 | 5 | 0.120 |
Why?
|
| Acinetobacter Infections | 1 | 2015 | 6 | 0.120 |
Why?
|
| Hematocrit | 1 | 2015 | 13 | 0.120 |
Why?
|
| Suction | 3 | 2011 | 36 | 0.120 |
Why?
|
| Private Practice | 1 | 1995 | 4 | 0.120 |
Why?
|
| Industry | 1 | 2015 | 4 | 0.120 |
Why?
|
| Surgical Flaps | 1 | 2015 | 50 | 0.120 |
Why?
|
| Insurance, Health | 1 | 1995 | 18 | 0.120 |
Why?
|
| Osteogenesis | 1 | 2016 | 101 | 0.120 |
Why?
|
| Nutrition Assessment | 1 | 2015 | 40 | 0.110 |
Why?
|
| Research Design | 1 | 2016 | 163 | 0.110 |
Why?
|
| Obesity | 1 | 2017 | 294 | 0.110 |
Why?
|
| Patients | 1 | 2015 | 31 | 0.110 |
Why?
|
| Perception | 1 | 2015 | 68 | 0.110 |
Why?
|
| Equipment Failure | 2 | 2013 | 35 | 0.110 |
Why?
|
| Sexual Behavior | 1 | 2014 | 49 | 0.110 |
Why?
|
| False Negative Reactions | 1 | 2014 | 13 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 154 | 0.110 |
Why?
|
| Seroma | 1 | 2014 | 4 | 0.110 |
Why?
|
| Posterior Cruciate Ligament | 2 | 2011 | 19 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 25 | 0.100 |
Why?
|
| Monitoring, Intraoperative | 1 | 2014 | 36 | 0.100 |
Why?
|
| Return to Work | 1 | 2014 | 40 | 0.100 |
Why?
|
| Treatment Failure | 4 | 2016 | 132 | 0.100 |
Why?
|
| Orthopedic Fixation Devices | 1 | 2013 | 18 | 0.100 |
Why?
|
| Physical Examination | 2 | 2011 | 94 | 0.100 |
Why?
|
| Aminoglycosides | 1 | 2013 | 10 | 0.100 |
Why?
|
| Platelet-Rich Plasma | 1 | 2013 | 40 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 72 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2013 | 65 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2013 | 27 | 0.100 |
Why?
|
| Bone Remodeling | 1 | 2013 | 48 | 0.100 |
Why?
|
| Bacteremia | 1 | 2013 | 98 | 0.100 |
Why?
|
| Triage | 1 | 2012 | 18 | 0.100 |
Why?
|
| Clinical Enzyme Tests | 1 | 2012 | 1 | 0.100 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 156 | 0.090 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 17 | 0.090 |
Why?
|
| Biocompatible Materials | 2 | 2017 | 71 | 0.090 |
Why?
|
| Spinal Fusion | 1 | 1999 | 429 | 0.090 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2011 | 10 | 0.090 |
Why?
|
| Substance P | 1 | 2011 | 10 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2013 | 58 | 0.090 |
Why?
|
| Norepinephrine | 1 | 2011 | 30 | 0.090 |
Why?
|
| Glutamic Acid | 1 | 2011 | 21 | 0.090 |
Why?
|
| Femoracetabular Impingement | 2 | 2013 | 223 | 0.090 |
Why?
|
| Causality | 1 | 2011 | 43 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2013 | 505 | 0.090 |
Why?
|
| Infant | 1 | 2013 | 488 | 0.090 |
Why?
|
| Work Capacity Evaluation | 1 | 2011 | 6 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 40 | 0.090 |
Why?
|
| Wound Closure Techniques | 1 | 2011 | 5 | 0.090 |
Why?
|
| Silicones | 1 | 2011 | 10 | 0.090 |
Why?
|
| Animals | 7 | 2016 | 3311 | 0.090 |
Why?
|
| Philadelphia | 1 | 2011 | 1 | 0.090 |
Why?
|
| Pedigree | 1 | 2011 | 51 | 0.090 |
Why?
|
| Data Collection | 3 | 2018 | 83 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 63 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2010 | 35 | 0.080 |
Why?
|
| Proteins | 1 | 2010 | 54 | 0.080 |
Why?
|
| International Normalized Ratio | 1 | 2010 | 18 | 0.080 |
Why?
|
| Phenotype | 1 | 2011 | 261 | 0.080 |
Why?
|
| Candida | 1 | 2009 | 16 | 0.080 |
Why?
|
| Mycoses | 1 | 2009 | 20 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 261 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2011 | 379 | 0.080 |
Why?
|
| Foreign-Body Migration | 1 | 2009 | 18 | 0.080 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2019 | 9 | 0.070 |
Why?
|
| Probability | 2 | 2004 | 73 | 0.070 |
Why?
|
| Canada | 2 | 2020 | 45 | 0.060 |
Why?
|
| Tendon Injuries | 2 | 2005 | 163 | 0.060 |
Why?
|
| Guided Tissue Regeneration | 1 | 2006 | 8 | 0.060 |
Why?
|
| Critical Pathways | 1 | 2006 | 19 | 0.060 |
Why?
|
| New York | 2 | 2003 | 9 | 0.060 |
Why?
|
| Vena Cava Filters | 2 | 2011 | 7 | 0.060 |
Why?
|
| Interviews as Topic | 3 | 2015 | 117 | 0.060 |
Why?
|
| Surface Properties | 2 | 2016 | 107 | 0.060 |
Why?
|
| Gait | 2 | 2016 | 383 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2003 | 25 | 0.050 |
Why?
|
| Polyethylenes | 1 | 2004 | 33 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 271 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 294 | 0.050 |
Why?
|
| Polymethyl Methacrylate | 1 | 2002 | 10 | 0.050 |
Why?
|
| Time and Motion Studies | 1 | 2022 | 16 | 0.050 |
Why?
|
| Propionibacterium acnes | 1 | 2022 | 6 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 26 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2022 | 55 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 29 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 34 | 0.050 |
Why?
|
| Hypersensitivity | 1 | 2002 | 38 | 0.050 |
Why?
|
| Dextrans | 1 | 2002 | 3 | 0.050 |
Why?
|
| School Admission Criteria | 1 | 2002 | 8 | 0.050 |
Why?
|
| Physician Executives | 1 | 2002 | 8 | 0.050 |
Why?
|
| Materials Testing | 2 | 2016 | 105 | 0.050 |
Why?
|
| Personnel Selection | 1 | 2002 | 19 | 0.050 |
Why?
|
| Groin | 1 | 2001 | 4 | 0.050 |
Why?
|
| Gene Expression | 2 | 2013 | 179 | 0.040 |
Why?
|
| Postural Balance | 1 | 2022 | 104 | 0.040 |
Why?
|
| Students, Medical | 1 | 2002 | 53 | 0.040 |
Why?
|
| Obturator Nerve | 1 | 2001 | 1 | 0.040 |
Why?
|
| Ontario | 1 | 2021 | 13 | 0.040 |
Why?
|
| Subacute Care | 1 | 2021 | 6 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2002 | 70 | 0.040 |
Why?
|
| Catastrophization | 1 | 2021 | 23 | 0.040 |
Why?
|
| Sciatic Nerve | 1 | 2001 | 23 | 0.040 |
Why?
|
| Anesthesia, Epidural | 2 | 2011 | 18 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 105 | 0.040 |
Why?
|
| Demography | 1 | 2020 | 58 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 140 | 0.040 |
Why?
|
| Cartilage | 1 | 2021 | 70 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 23 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 54 | 0.040 |
Why?
|
| Rib Fractures | 1 | 2000 | 1 | 0.040 |
Why?
|
| Current Procedural Terminology | 1 | 2019 | 11 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2000 | 52 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 14 | 0.040 |
Why?
|
| Solutions | 1 | 2019 | 15 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2012 | 778 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 2019 | 6 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2000 | 75 | 0.040 |
Why?
|
| Gentian Violet | 1 | 1999 | 3 | 0.040 |
Why?
|
| Phenazines | 1 | 1999 | 4 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 1999 | 15 | 0.040 |
Why?
|
| Pain Perception | 1 | 2019 | 5 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2000 | 46 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2016 | 315 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1999 | 40 | 0.040 |
Why?
|
| Glycoproteins | 1 | 1999 | 42 | 0.040 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 1999 | 11 | 0.040 |
Why?
|
| Medicare Access and CHIP Reauthorization Act of 2015 | 1 | 2018 | 1 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2018 | 4 | 0.040 |
Why?
|
| Models, Economic | 1 | 2018 | 7 | 0.040 |
Why?
|
| Chondrosarcoma | 1 | 1998 | 41 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 1998 | 43 | 0.040 |
Why?
|
| Rupture | 2 | 2012 | 86 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 1998 | 73 | 0.040 |
Why?
|
| Medicaid | 1 | 2018 | 36 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 10 | 0.040 |
Why?
|
| Pregnancy | 2 | 2014 | 322 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2018 | 12 | 0.040 |
Why?
|
| Electromyography | 1 | 2018 | 68 | 0.040 |
Why?
|
| Creatinine | 1 | 2018 | 41 | 0.040 |
Why?
|
| Absorption, Physiological | 1 | 2017 | 2 | 0.030 |
Why?
|
| Colitis | 1 | 2017 | 25 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 146 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 1998 | 127 | 0.030 |
Why?
|
| Smoking | 1 | 2018 | 168 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2017 | 49 | 0.030 |
Why?
|
| Kidney | 1 | 2017 | 144 | 0.030 |
Why?
|
| Self Concept | 1 | 2016 | 37 | 0.030 |
Why?
|
| Exploratory Behavior | 1 | 2016 | 9 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 237 | 0.030 |
Why?
|
| Societies | 1 | 2016 | 6 | 0.030 |
Why?
|
| Injections | 1 | 2016 | 42 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2016 | 46 | 0.030 |
Why?
|
| Midwestern United States | 1 | 2016 | 46 | 0.030 |
Why?
|
| Bacterial Adhesion | 1 | 2015 | 3 | 0.030 |
Why?
|
| Noise | 1 | 2016 | 24 | 0.030 |
Why?
|
| Drug Resistance, Multiple | 1 | 2015 | 12 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2016 | 66 | 0.030 |
Why?
|
| Biofilms | 1 | 2015 | 14 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2016 | 24 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 162 | 0.030 |
Why?
|
| Rabbits | 1 | 2016 | 169 | 0.030 |
Why?
|
| Medical Assistance | 1 | 1995 | 2 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 30 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 1995 | 12 | 0.030 |
Why?
|
| Cell Line | 1 | 2015 | 250 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 60 | 0.030 |
Why?
|
| Placenta | 1 | 2014 | 5 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2014 | 11 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2015 | 23 | 0.030 |
Why?
|
| Global Health | 1 | 2015 | 32 | 0.030 |
Why?
|
| Nickel | 1 | 2014 | 20 | 0.030 |
Why?
|
| Health Surveys | 1 | 2014 | 80 | 0.030 |
Why?
|
| Hematologic Tests | 1 | 2014 | 6 | 0.030 |
Why?
|
| Motor Activity | 1 | 2016 | 275 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2014 | 17 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2013 | 19 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 30 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 38 | 0.030 |
Why?
|
| Disease Progression | 2 | 2006 | 530 | 0.030 |
Why?
|
| Social Class | 1 | 2014 | 55 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 78 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 2013 | 34 | 0.030 |
Why?
|
| Aggrecans | 1 | 2013 | 51 | 0.030 |
Why?
|
| Collagen | 1 | 2013 | 81 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2013 | 70 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 134 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 528 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 235 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 88 | 0.030 |
Why?
|
| Osteonecrosis | 1 | 2013 | 14 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2014 | 538 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 170 | 0.020 |
Why?
|
| Anthropometry | 1 | 2012 | 29 | 0.020 |
Why?
|
| California | 1 | 2012 | 35 | 0.020 |
Why?
|
| Fees and Charges | 1 | 2012 | 4 | 0.020 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2011 | 5 | 0.020 |
Why?
|
| Staphylococcus | 1 | 2011 | 7 | 0.020 |
Why?
|
| Pennsylvania | 1 | 2011 | 6 | 0.020 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2011 | 20 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 2011 | 23 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2011 | 31 | 0.020 |
Why?
|
| Hemophilia A | 1 | 2011 | 48 | 0.020 |
Why?
|
| Workload | 1 | 2011 | 27 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 107 | 0.020 |
Why?
|
| Educational Status | 1 | 2012 | 214 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 203 | 0.020 |
Why?
|
| Polymethacrylic Acids | 1 | 2010 | 4 | 0.020 |
Why?
|
| Anterior Cruciate Ligament Injuries | 1 | 2012 | 143 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2010 | 51 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 67 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 112 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2009 | 27 | 0.020 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 23 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 1999 | 285 | 0.020 |
Why?
|
| Connective Tissue | 1 | 2007 | 20 | 0.020 |
Why?
|
| Sleep | 1 | 2009 | 270 | 0.020 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2008 | 113 | 0.020 |
Why?
|
| Research | 1 | 2006 | 36 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2006 | 55 | 0.020 |
Why?
|
| Supine Position | 1 | 2006 | 17 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2006 | 209 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 196 | 0.010 |
Why?
|
| Weight-Bearing | 1 | 2004 | 138 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 245 | 0.010 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2002 | 15 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2002 | 58 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2000 | 4 | 0.010 |
Why?
|
| Abdominal Pain | 1 | 2000 | 6 | 0.010 |
Why?
|
| Cough | 1 | 2000 | 9 | 0.010 |
Why?
|
| Cartilage Oligomeric Matrix Protein | 1 | 1999 | 1 | 0.010 |
Why?
|
| Matrilin Proteins | 1 | 1999 | 3 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1999 | 2 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1999 | 32 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1999 | 49 | 0.010 |
Why?
|
| Guanidines | 1 | 1998 | 1 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 1998 | 11 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 1998 | 64 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1998 | 87 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1998 | 144 | 0.010 |
Why?
|
| Rats | 1 | 1998 | 624 | 0.010 |
Why?
|